|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM275540715 |
| 003 |
DE-627 |
| 005 |
20231225005917.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2017.09.004
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0918.xml
|
| 035 |
|
|
|a (DE-627)NLM275540715
|
| 035 |
|
|
|a (NLM)28882620
|
| 035 |
|
|
|a (PII)S1521-6616(17)30041-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Melsted, Wenna Nascimento
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a HLA class Ia and Ib molecules and FOXP3+ TILs in relation to the prognosis of malignant melanoma patients
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.12.2017
|
| 500 |
|
|
|a Date Revised 30.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2017 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a HLA class Ia (HLA-ABC) and HLA class Ib (HLA-E, -F and -G) molecules and FOXP3+ tumor-infiltrating lymphocytes (TILs) are often reported as relevant factors of tumor immune regulation. We investigated their expression as prognostic factors in 200 patients with primary cutaneous melanoma (PCM). In our cohort, patients with tumors showing upregulation of HLA-ABC molecules had significantly thicker tumors (32% vs 7%, P<0.001), frequent ulceration (20% vs 6%, P=0.007) and frequent nodular melanomas (20% vs 4%, P=0.001). Additionally, high expression of HLA-G in the tumor was a sign of bad prognosis for the patients, being associated with thick tumors (30% vs 12%, P=0.017), ulceration (24% vs 5%, P<0.001) and positive sentinel node (13% vs 6%, P=0.015). HLA-E, HLA-F and FOXP3+ TILs were not indicative of the prognosis in PCM. High HLA-ABC and HLA-G were associated with tumor aggressiveness and could be relevant predictive markers for effective immunotherapy of melanoma tumors
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a FOXP3+
|
| 650 |
|
4 |
|a HLA
|
| 650 |
|
4 |
|a Malignant melanoma
|
| 650 |
|
4 |
|a Prognosis
|
| 650 |
|
4 |
|a Regulatory T cells
|
| 650 |
|
7 |
|a FOXP3 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
| 700 |
1 |
|
|a Johansen, Lasse Lindholm
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lock-Andersen, Jørgen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Behrendt, Nille
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Eriksen, Jens Ole
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bzorek, Michael
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Scheike, Thomas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hviid, Thomas Vauvert F
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 183(2017) vom: 04. Okt., Seite 191-197
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:183
|g year:2017
|g day:04
|g month:10
|g pages:191-197
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2017.09.004
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 183
|j 2017
|b 04
|c 10
|h 191-197
|